Business context and reporting period
The supplied filing is On Assignment, Inc.’s Form 10-K for the fiscal year ended December 31, 2012, not a filing identified as Everforth Inc. It reports the fourth quarter as well as the full fiscal year; amounts below are in U.S. dollars. On Assignment provides contract, contract-to-hire, and direct-hire staffing in technology, life sciences, healthcare, and physician services.
Results include Apex Systems from its May 15, 2012 acquisition. Consequently, reported full-year growth is not directly comparable with 2011. The filing also provides unaudited pro forma results as if Apex had been acquired at the beginning of 2011.
Financial performance and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue | $1,239.7 million | $597.3 million |
| Gross profit / margin | $384.3 million / 31.0% | $200.1 million / 33.5% |
| Operating income / margin | $92.8 million / 7.5% | $44.4 million / 7.4% |
| Net income / margin | $42.7 million / 3.4% | $24.3 million / 4.1% |
| Diluted EPS | $0.89 | $0.64 |
| Operating cash flow | $40.7 million | $23.4 million |
Fourth-quarter 2012 revenue was $401.7 million, gross profit $121.3 million, net income $11.3 million, and diluted EPS $0.21. Fourth-quarter 2011 figures were $161.8 million, $53.6 million, $7.5 million, and $0.20, respectively; the acquisition materially affects the comparison.
At year-end, cash was $27.5 million, working capital $175.0 million, and total debt $426.6 million. The company had $72.2 million available under its credit facility and reported a 2.73x leverage ratio, within covenant limits. Investing cash outflow was $363.0 million, including $347.7 million for acquisitions; financing cash inflow was $331.9 million. Capital expenditures were $14.4 million, and management estimated approximately $16.0 million for 2013.
Material changes and segment performance
- Revenue increased 107.6%, primarily due to Apex, which contributed $508.7 million, or 41.0% of consolidated revenue, for the period owned. Excluding Apex, the filing reports 22.4% year-over-year growth across the other segments.
- Oxford revenue grew 29.5% to $345.4 million; Life Sciences grew 4.8% to $162.8 million; Healthcare grew 27.0% to $120.1 million; and Physician grew 27.4% to $102.7 million.
- Consolidated gross margin contracted by 250 basis points, chiefly because Apex had a lower gross margin than the company’s other segments. Higher interest expense ($17.8 million versus $2.9 million) reflected acquisition-related borrowing. Amortization rose to $18.0 million from $2.3 million, largely from Apex acquired intangibles.
- SG&A was $273.5 million, including $10.6 million of acquisition costs. Apex recorded $508.7 million revenue and a $7.3 million net loss in its partial-year contribution.
- Pro forma results, assuming Apex was acquired at the start of 2011, show 2012 revenue of $1,522.0 million and net income of $55.6 million, compared with 2011 revenue of $1,316.2 million and net income of $26.1 million. These unaudited figures are not necessarily indicative of actual or future results.
Outlook, risks, and unusual items
Management anticipated improving markets alongside the economy, continued investment in existing businesses, and further review of acquisition opportunities. A new strategic-planning process was expected to conclude around mid-2013. The filing cites third-party 2013 staffing-market growth estimates, including 8% for IT and healthcare staffing and 9% for physician staffing; these are industry estimates, not company guidance. No specific company revenue or earnings guidance is provided.
In February 2013, the company sold its Nurse Travel business for $31.0 million cash; it had represented approximately 5% of 2012 revenue. Management described it as non-core and noted its lower margins and difficulty achieving scale. Goodwill and identifiable intangible assets totaled approximately $762.2 million at year-end; no 2012 impairment was recorded, but valuation depends on forecasts and assumptions. Key risks include economic cyclicality, short-notice termination of assignments, competition and pricing pressure, recruiting and retention, healthcare reimbursement and regulation, insurance and payroll costs, acquisition integration, debt covenants and interest rates, and potential legal or worker-classification claims. Management said working capital, expected operating cash flow, and the credit facility should fund requirements for the next 12 months.
Other notable matters: the 2012 effective tax rate was 43.1%; potential acquisition earn-outs were approximately $9.1 million through 2013; and the auditor issued an unqualified opinion on the financial statements and internal controls. Apex was excluded from management’s 2012 internal-control assessment, although management reported effective controls for the company overall. An immaterial $0.5 million Apex vendor-fee classification correction was disclosed, with no effect on the balance sheet or cash flows.
Important facts for investors to verify
- Separate Apex’s partial-year contribution from underlying organic growth; compare reported and pro forma figures with their stated limitations.
- Assess whether margin pressure, higher acquisition-related amortization and financing costs, and the reported Apex loss persist or improve.
- Review debt repayment terms, variable-rate exposure, hedging, covenant headroom, and the company’s ability to generate cash while funding working capital.
- Confirm the Nurse Travel sale’s closing, proceeds, transition costs, and effect on the remaining Healthcare segment.
- Monitor goodwill and intangible-asset assumptions, outstanding earn-outs, insurance reserves, and the integration and internal-control treatment of Apex.